Fasudil hydrochloride injection of HongRi Pharmaceutical Co., Ltd. entered the site for inspection this month
-
Last Update: 2014-10-20
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
HongRi pharmaceutical securities office said that the application for fasudil hydrochloride injection is a supplementary application, mainly for process improvement to improve product quality At the same time, she stressed that although the market competition for this product is fierce at present, the company will try to do it well Fasudil hydrochloride injection is a Rho kinase inhibitor, which is mainly used to improve the symptoms of ischemic cerebrovascular disease caused by cerebral vasospasm after subarachnoid hemorrhage According to the report for the half year of 2014, the sales volume of the product is about 102 million, with a growth rate of about 8.51%, which is lower than the market expectation According to the market participants, the main reason for the slowdown in the growth rate of fasudil hydrochloride injection is that there are currently 13 enterprises approved to produce the product, the fierce competition among the manufacturers leads to the continuous decline of the bid price, and in addition to the competition from the newly approved fasudil mesylate At present, the main products of HongRi pharmaceutical industry are concentrated in the field of cardio cerebrovascular, among which fasudil hydrochloride injection is one of the main products of the company, and its reported revenue in the half year of 2014 accounts for about 10% of the company's total revenue.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
